• Home
  • About
  • ‘Enforcement 40’ for 2020
  • Webcasts
  • Enforcement Hall of Fame
  • Contact
Securities Docket
Experts in Risk
  • Class Actions
  • Criminal
  • Events
  • Features
  • Global
  • People
  • SEC
Browse: Home / 2012 / February / 15 / Pfizer Knocks Out Securities Class Action Over Alzheimer’s Drug

Pfizer Knocks Out Securities Class Action Over Alzheimer’s Drug

By Securities Docket on February 15, 2012, 2:36 pm

On Friday, Newark, N.J., federal district court judge Susan Wigenton granted a motion to dismiss class action securities fraud claims pending since June 2010 against Pfizer and five former Wyeth executives. In a 14-page decision, Judge Wigenton concluded that the named plaintiff failed to adequately plead that the defendants misled investors about the success of clinical trials for bapineuzumab, a potential blockbuster drug developed by Pfizer and Elan to slow or prevent the effects of Alzheimer’s.

via Pfizer Knocks Out Securities Class Action Over Alzheimer’s Drug — AmLaw Litigation Daily

Posted in Class Actions, Top | Tagged Dismissals

« Previous Next »

Subscribe

‘Enforcement 40’ for 2020

Our Sponsors

Securities-Docket_260x125_14Sec

Join Us On LinkedIn

Join the Securities Litigation and Enforcement Group on LinkedIn

Archives

Copyright © 2023 Securities Docket.

  • Home
  • About
  • ‘Enforcement 40’ for 2020
  • Webcasts
  • Enforcement Hall of Fame
  • Contact
  • Criminal
  • Class Actions
  • Features
  • Global
  • People
  • SEC
  • Events